2023-11-14 04:31:48
One dose of an experimental drug from the giant Eli Lilly can reduce one of the heart risk markers by 94% for almost a year, writes Bloomberg with reference to the results of the first phase of clinical trials of the drug. If not a panacea, then a clearly significant breakthrough in the prevention of cardiovascular diseases was called Lepodisiran.
According to the company, in the main group of subjects, the drug demonstrated an almost 20-fold reduction in the concentration of so-called lipoprotein (a). Elevated levels of the substance are associated with a high risk of coronary heart disease, atherosclerosis, thrombosis, stroke and other heart diseases. Muraz Shambatov, a cardiologist at the Doctis telemedicine service, says:
Muraz Shambatov, cardiologist at Doctis telemedicine service
As Bloomberg points out, medicine does not yet know any drugs with proven effectiveness that can reduce lipoprotein (a) levels. According to the article, its elevated concentrations place more than 1 billion people around the world at moderate to high risk for heart disease, which remains the leading cause of death. Alfred Bogdanov, head of the department of cardiovascular pathology at the Clinic of the Research Institute of Nutrition of the Russian Academy of Medical Sciences, comments:
Alfred Bogdanov, Head of the Department of Cardiovascular Pathology, Clinic of the Research Institute of Nutrition of the Russian Academy of Medical Sciences
An additional benefit of Eli Lilly’s experimental drug is how long it lasts. According to the company, Lepodisiran continued to have an effect on lipoprotein(a) concentrations up to a year following administration. Bloomberg hopes the drug might become something of a “vaccine” once morest heart risks. The first phase of trials was aimed at testing the safety of the drug, and it is now undergoing wider testing for effectiveness. The timing of the drug’s availability on the market has not yet been announced.
1699966539
#Pharmacists #hope #defeat #main #risk #factors #atherosclerosis
